#retinaldiseases kết quả tìm kiếm

How can longer-acting #AntiVEGF therapies help reduce treatment burden in #RetinalDiseases? Watch this on-demand CME/AAPA program exploring new formulations, delivery systems, and individualized treatment strategies: bit.ly/3WHXAsE

🎉 This paper was cited 57 times! 📊 👉Artificial Intelligence (AI) for Early #Diagnosis of #RetinalDiseases 🔗 Link: brnw.ch/21x1lO7 📝 by Uday Pratap et al. #mdpimedicina #highlycited #ophthalmology

Frequent #AntiVEGF injections can create treatment burden and impact adherence in #RetinalDiseases. Learn how longer-acting strategies may help reduce burden and improve outcomes in this on-demand CME/AAPA program. Watch now! bit.ly/3WHXAsE

#BreakingNews: The U.S. FDA has approved our medicine for certain #RetinalDiseases as the first and only injectable anti-VEGF with dosing intervals up to 5 months following one year of successful response based on visual and anatomic outcomes. bit.ly/41KMwgM

RetinalGeniX and RGEN announce a strategic collaboration to advance early detection of #neurodegenerative, systemic, and #retinaldiseases. Read the press release: bit.ly/3Wfpg7V $RTGN

Thank you to Peter A. Campochiaro, MD, & Joseph Toscano, MD, FCUCM, for an insightful discussion at our #RetinalDiseases virtual workshops! Your expertise brought real-world impact to these conversations. Missed it? Catch the replay here: bit.ly/RetinalUC25T #CME #MedEd

Diagnosis and Management of #RetinalDiseases in #UrgentCare: Boost your skills in identifying retinal emergencies. Second chance for live chat Q&A w/ Peter A. Campochiaro, MD, & Joseph Toscano, MD, FCUCM! 9/23 at 7:00 PM EDT. bit.ly/RetinalUC25T #CME #ophthalmology

🔎 The @ResearchKarger #Ophthalmology publications address the management of #RetinalDiseases using new imaging methods and therapy #CaseReports, as well as surgical treatment of, for example, #OphthalmicCancer. 🔬👁️

Enhancing Diagnosis and Management of #RetinalDiseases in #UrgentCare: Spot retinal emergencies fast in urgent care, with Peter A. Campochiaro, MD, & Joseph Toscano, MD, FCUCM, on 9/9 & 9/23. bit.ly/RetinalUC25T #ophthalmology

(PSA) Retina Clinic Every Tuesday at DSSEH dsseh.com/blog/ #Retina #retinaldiseases #diabeticRetinopathy #ARMD #AgeRelatedMacularDisease #EyeInjections #intraVitrealInjections #AntiVEGF

Remember to join us 9/9 & 9/23 for our #RetinalDiseases in #UrgentCare virtual workshops. Please tweet your questions in advance and follow @PeerView for more #MedEd content! bit.ly/RetinalUC25T #ophthalmology

Novel #TCM Prescription for #RetinalDiseases Exploring a new traditional Chinese medicine formula containing Chrysanthemi Flos for glaucoma, diabetic retinopathy, and age-related macular degeneration! Read more: doi.org/10.53388/TMR20…

During National Eye Exam Month, explore this #CME activity for early-career vitreoretinal specialists and comprehensive ophthalmologists, that focuses on opportunities to personalize treatment plans for patients with #retinaldiseases. nexusmedx.com/courses/40 #CatalystMedEd

👁️‍🗨️ Discover the Common Retinal Diseases You Should Know About 📍 Pushpanjali Eye Care Hospital, Golpark, Kolkata-700029 📞 +91 90511 55660 | +91 98741 44440 Visit: postiyo.great-site.net/common-retinal… #EyeCare #RetinalDiseases #HealthyVision #MacularDegeneration

BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases bayer.com/media/en-us/bl… #OpCT001 #iPSC #RetinalDiseases #PhotoreceptorDisorders #CellTherapy

Via #OPG_BOEx: Classifying retinal diseases via pyramid vision graph convolutional network for optical coherence tomography images bit.ly/44iEJaZ #DeepNeuralNetworks #RetinalDiseases

OPEN ACCESS Article DRUSEN VOLUME AS CLINICAL OUTCOME MEASURE IN SUBJECTS WITH MALATTIA LEVENTINESE Ehrenzeller, Clara BSc; et. al. Retina 45(6):p 1192-1199, June 2025 journals.lww.com/retinajournal/… #retina #retinaldiseases #translationalresearch #clinicaloutcomemeasures

How is the diagnostic and treatment landscape for #RetinalDiseases evolving and delivering better visual outcomes? Our experts discuss these groundbreaking advances and more, in our upcoming live webinar. Register now 👉 buff.ly/4CCsXfv #EyeMed #retinopathy #VEGF

The diagnostic and treatment landscape for #RetinalDiseases is rapidly evolving. Explore groundbreaking advances in retinal imaging and gene therapy, before taking a deep dive into emerging treatments for wet #AMD. Register now 👉 buff.ly/4CCsXfv #Ophthalmology #EyeMed

👁️🦠The gut microbiota is a dynamic microbial network influencing systemic and organ-specific health. This review highlights emerging evidence for a gut–retina axis, linking dysbiosis to retinal diseases. 🔗 mdpi.com/2076-2607/13/5… #GutMicrobiota #GutRetinaAxis #RetinalDiseases

🎉 This paper was cited 57 times! 📊 👉Artificial Intelligence (AI) for Early #Diagnosis of #RetinalDiseases 🔗 Link: brnw.ch/21x1lO7 📝 by Uday Pratap et al. #mdpimedicina #highlycited #ophthalmology

From various stages of #glaucoma to #RetinalDiseases, our #EyeCare scientists use innovative approaches to investigate some of the major causes of #VisionLoss. Learn how: bit.ly/3Nql7tc

Curious about new therapies for treating retinal diseases? Join Aleksandra Rachitskaya, MD, and Jordan Graff, MD, FACS, for a new series on the latest drug delivery methods and treatment approaches. Watch now: ow.ly/vqtE50UwzHb #retinaldiseases #newtherapies

Congrats to Prof. Wong Tien Yin for being selected for the @OphthoMag Power List 2024, where he ranks 13th! This honor recognizes him for leading professional guidelines on #RetinalDiseases and #Myopia to improve diagnosis, treatment, and prevention. More: bit.ly/3WHb2Ou

Congratulations to @GlennYiuMD (@UofCalifornia) — winner of the 2024 Carl Camras Translational Research Award. Read about his cutting-edge translational research on #RetinalDiseases using gene editing, ocular imaging and animal models: bit.ly/3vTrtvY #VisionResearch

👁️✨ Advancing precision in retinal disease detection. Innovative diagnostic approaches are reshaping ophthalmic care. 👨‍⚕️ Guest Editors: Dr. Benedetto Falsini & Prof. Dr. Andrea Cusumano ⏳ Deadline: 30 Sept 2026 🔗 mdpi.com/journal/diagno… #RetinalDiseases #Ophthalmology

❗The #ASRS2024 coverage continues!❗ Interim safety data from a post-authorization study of #Luxturna in patients with genetic #retinaldiseases were consistent with clinical trial data. Find out more 👇 #OcularSurgeryNews @asrsdocs healio.com/news/ophthalmo…

#specialissues #submissionswelcome 💡#RetinalDiseases: Clinical Presentation and Novel Treatments 🔗mdpi.com/journal/medici… 🧑‍🔬Guest Editor: Dr. Joshua Ong and Dr. Jay Chhablani 📅Deadline: 31 August 2024

Join Drs. Peter A. Campochiaro & Diana Do on 2/24 or 3/3 at 7:00 PM EST for a #RetinalDiseases #MedEd event: bit.ly/RetinalDisease… #ophthalmology

Diagnosis and Management of #RetinalDiseases in #UrgentCare: Boost your skills in identifying retinal emergencies. Second chance for live chat Q&A w/ Peter A. Campochiaro, MD, & Joseph Toscano, MD, FCUCM! 9/23 at 7:00 PM EDT. bit.ly/RetinalUC25T #CME #ophthalmology

Via #OPG_BOEx: Classifying retinal diseases via pyramid vision graph convolutional network for optical coherence tomography images bit.ly/44iEJaZ #DeepNeuralNetworks #RetinalDiseases

1/@BeaconTx_ is launched with £96M ~ $120M to develop a new generation of #GeneTherapy for #retinaldiseases resulting in #blindness. The funding came from its leading investor @SynconaLtd & other investors such as @OxfordSciEnt to progress Beacon’s pipeline. #BioTech #Genomics

Remember to join us tomorrow, 3/3 at 7:00 PM EST for a live rebroadcast of our #RetinalDiseases virtual symposium, with a faculty-led Q&A to discuss practical strategies for improving patient outcomes. Register here: bit.ly/RetinalDisease… #ContinuingEducation

Innovations in Neovascular #RetinalDiseases: Learn more on enhancing patient outcomes with Drs. Peter A. Campochiaro & Diana Do on 2/24 or 3/3 at 7:00 PM EST. Register ➡️ bit.ly/RetinalDisease… #ophthalmology

Congratulations to Dr Jörn Lakowski, who has successfully secured a 3-year academic grant of £548k from the Biotechnology and Biological Sciences Research Council for his work on #inherited #retinaldiseases, including #RetinitisPigmentosa. @UHSFT @unisouthampton #visionresearch

#CallforSubmissions to touchREVIEWS in Ophthalmology. Topics of interest include, but are not limited to, the treatments in #RetinalDiseases. Submission deadline: August 30th 2023 Learn more and submit here: bit.ly/3iYm5RB

#BreakingNews: The U.S. FDA has approved our medicine for certain #RetinalDiseases as the first and only injectable anti-VEGF with dosing intervals up to 5 months following one year of successful response based on visual and anatomic outcomes. bit.ly/41KMwgM

Attending the ERN-EJPRD workshop on new #therapies for #retinaldiseases in Valencia.